Century Therapeutics, Inc.
IPSCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCentury Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. At a $264.4M market cap, Century Therapeutics, Inc. ranks as a micro-cap company within healthcare. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Market Cap
$264.4M
Beta
1.67
P/E (TTM)
—
P/E (Fwd)
-3.24
EPS (TTM)
$-0.93
EPS (Fwd)
$-0.45
ROE
-49.6%
ROA
-23.5%
Cash
$119.7M
Total Debt
$38.7M
Free CF
-$50.4M
52W Change
143.3%
Annual Financials
Cash vs Debt
Where IPSC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IPSC finished 30.33% below its 150-day moving average ($2.11) and 30.00% below its 200-day moving average ($2.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IPSC overbought or oversold?
At the October 20, 2026 close, IPSC's RSI(14) was 42.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Century Therapeutics, Inc. holds $119.7M in cash against $38.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$50.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -49.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $5.2M (2022) to $109.2M (2025), reflecting a 2000% increase over the period.
Century Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing IPSC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.